Peptides in Sleep Research: DSIP, Epitalon and the GH-Sleep Axis
Three different ways peptides intersect with sleep research: DSIP's weak delta-sleep hypothesis, Epitalon's pineal-melatonin circadian angle, and the growth-hormone-slow-wave-sleep axis where GHRH analogues sit.
TL;DR: Three different sleep-research angles, none of them a sleep aid
"Peptides for sleep" is three separate stories, not one, and none of these is an established hypnotic. DSIP (delta-sleep-inducing peptide) was named for a 1977 sleep hypothesis that is now judged weak and partly contradicted: plasma DSIP-like immunoreactivity was actually lower during slow-wave and REM sleep (PMID 8175965, 16539679). Epitalon has not been shown to act as a direct sedative in the cited evidence. It is studied upstream, on the pineal gland, and was reported to restore the nocturnal melatonin rhythm in aged models (PMID 17969590), largely by a single research group. The GH-sleep axis is real: growth hormone is secreted at sleep onset during slow-wave sleep, and exogenous GHRH raised slow-wave sleep in one cited study (PMID 1361964). The stocked GHRH analogues sermorelin and CJC-1295 sit in this axis mechanistically, but there is no cited human sleep-quality data for them.
Peptides keep appearing in sleep research, but for three completely different reasons, and lumping them into a "best peptides for sleep" list misrepresents all three. This article separates them: DSIP and its shaky delta-sleep story, Epitalon and the pineal-melatonin circadian angle, and the growth-hormone-slow-wave-sleep axis where GHRH analogues belong. It is a mechanism-and-evidence explainer for laboratory research context only, with no dosing, no protocols and no sleep-disorder treatment claims. Historical human studies are reported as research history, not usage guidance.
Neuroprotective and nootropic peptides
DSIP: A Famous Name, a Weak Hypothesis
DSIP is a nonapeptide isolated from rabbit cerebral venous blood in 1977 and initially proposed as a sleep-promoting factor. The name has stuck far better than the evidence.
The delta-sleep hypothesis is poorly documented (PMID 16539679, 8175965)
A 2006 review concluded that the link between DSIP and sleep "has never been further characterized" and called the sleep-factor hypothesis "extremely poorly documented and still weak"; no DSIP gene or receptor has been isolated (PMID 16539679). Worse for the simple story: plasma DSIP-like immunoreactivity follows a diurnal rhythm that tracks body temperature and is lower during slow-wave and REM sleep, which argues against a straightforward sleep-inducing role (PMID 8175965).
The human trials do not rescue it. An early study in six chronic insomniacs reported that intravenous DSIP lengthened sleep with the effect emerging mainly in the second hour (PMID 7028502), but that work came from the discovering group. An independent double-blind crossover trial found DSIP raised total and NREM sleep mainly via stage 2, with no statistically significant improvement over placebo, and concluded the effect was "of little clinical significance" (PMID 3583493). The honest summary (one such independent trial): DSIP is a scientifically interesting unsolved puzzle, not an established sleep aid.
DSIP (Delta Sleep-Inducing Peptide), a nonapeptide isolated in 1977. Research material for sleep, HPA-axis, and stress regulation. Research-grade lyophilized powder, laboratory use only.
Epitalon: Not a Sedative, a Circadian Angle
Epitalon (the tetrapeptide Ala-Glu-Asp-Gly, AEDG) belongs in a sleep-research article for a different reason: it is not studied as a hypnotic, but as an upstream regulator of the pineal melatonin rhythm. Melatonin is the pineal hormone secreted during darkness that conveys the circadian night signal and helps entrain sleep timing, and Epitalon's proposed relevance is restoring that endogenous rhythm rather than acting as a direct sedative.
Melatonin-rhythm restoration in aged models (PMID 15452611, 17969590, 11524632)
A course of the parent pineal extract Epithalamin was reported to exert a normalizing effect on circadian melatonin: elderly subjects with reduced pineal activity showed increased nighttime melatonin, while those with normal function showed a slight reduction, meaning rhythm normalization rather than uniform elevation (PMID 15452611). Both Epithalamin and synthetic Epitalon were reported to recover nocturnal melatonin release and normalize the melatonin rhythm in aged monkeys and elderly people with pineal insufficiency (PMID 17969590), and in senescent macaques Epitalon was reported to stimulate evening melatonin and normalize the cortisol rhythm (PMID 11524632).
Read the Epitalon literature as claims
Epitalon's circadian-melatonin evidence comes largely from a single St. Petersburg research group, is mostly unblinded, and has not been independently replicated; a 2025 review notes it remains uncertain whether melatonin and telomerase effects are the sole mechanisms and that structural data are limited (PMID 40141333). Its telomerase and anti-aging findings are preclinical and out of scope here. Treat the circadian claims as reported, not proven.
Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.
The GH-Sleep Axis: Where GHRH Analogues Actually Sit
The third and best-characterized connection is not about a "sleep peptide" at all. It is the tight physiological link between growth hormone and deep sleep.
GH is secreted in pulses with the dominant pulse at sleep onset, coincident with the first slow-wave-sleep episode, and this pulse follows the sleep schedule rather than an independent clock (PMID 4307378). GH is preferentially secreted during deep slow-wave sleep, and the sleep-onset pulse reflects GHRH drive during a trough in somatostatin tone, with ghrelin contributing (PMID 15135771). Crucially, intravenous GHRH increased slow-wave sleep in one cited human study: in healthy men it raised nocturnal GH and slow-wave sleep while lowering cortisol (PMID 1361964), though antagonist evidence (below) challenges a necessary causal role in generating slow-wave sleep.
Coupled but dissociable, and not a claim for the stocked analogues
The coupling is real but the causal arrow is contested: giving GHRH raises slow-wave sleep (PMID 1361964), yet a GHRH antagonist suppressed about 93 percent of nocturnal GH without reducing slow-wave sleep (PMID 15538933). So GHRH is necessary for the GH pulse but is unlikely to generate slow-wave sleep on its own. Just as important: sermorelin (GHRH 1-29) and CJC-1295 are GHRH-receptor agonists, the exogenous analogues of the endogenous GHRH in these studies, but there is no cited human sleep-quality data for the stocked analogues themselves. Their link to sleep is mechanistic, through the GH axis, not a demonstrated sleep benefit.
The GH-secretagogue arm makes the same point: the GH signal does not map onto one sleep outcome. Endogenous ghrelin increased slow-wave sleep and delta activity while raising GH (PMID 12388174), whereas the synthetic secretagogue GHRP-6 raised GH but increased only stage 2 sleep and left slow-wave sleep unchanged, while also raising cortisol (PMID 7617137). (Ghrelin and GHRP-6 are discussed here only as research context and are not offered for sale.)
Delta-sleep / DSIP research
Pineal / circadian-rhythm research
GH-sleep axis research (mechanistic, not a sleep claim)
At a Glance
- Sleep-research angle
- Proposed direct delta-sleep factor
- Evidence
- Weak, old, partly contradicted
- Stocked
- Yes
- Sleep-research angle
- Upstream pineal / melatonin-rhythm restoration
- Evidence
- Single-group, unblinded, reported
- Stocked
- Yes
- Sleep-research angle
- GHRH arm of the GH-slow-wave-sleep axis
- Evidence
- Mechanistic only; no sleep-quality data for the analogues
- Stocked
- Yes
What the Evidence Does Not Show
None of these is a demonstrated treatment for insomnia or any sleep disorder. DSIP's sleep effect is weak and inconsistent; Epitalon is a circadian-rhythm research compound, not a sedative, and its data is largely single-group; and the GH-sleep axis links GHRH to slow-wave sleep physiologically without establishing that the stocked GHRH analogues improve human sleep. Anything framing these as sleep aids goes beyond the evidence.
Research Context and Handling
DSIP, Epitalon, sermorelin and CJC-1295 are supplied strictly for laboratory research and are not intended for human consumption. Epithalamin, ghrelin, GHRP-6 and gamma-hydroxybutyrate are discussed only as scientific context and are not offered for sale. This article gives no dosing or administration guidance; historical human study parameters belong to their cited studies. Verify identity and purity against a batch-specific third-party Certificate of Analysis. For the single-compound detail, see the DSIP research guide and the Epitalon overview.
Frequently Asked Questions
This article is for research and educational purposes only. Sleep, circadian and endocrine findings are described for scientific context; conditions are named only to describe what published research investigated. Nothing here is medical advice, a health claim, dosing guidance or a recommendation for use. All stocked compounds mentioned are sold exclusively for laboratory research.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.